Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07142954 · ClinicalTrials.gov registry record · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
A Phase 3 study of Alzheimer Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 3,400
- Enrollment target
- 3
- Study locations
NCT07142954: Recruiting Phase 3 study of Alzheimer Disease, sponsored by Eli Lilly and Company.
NCT07142954 is a Phase 3 study of Alzheimer Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 3,400 participants, above the 2,740-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (24% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07142954, a Phase 3 study of Alzheimer Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,400 participants
- Enrollment target
- 3
- Study locations
Study Summary
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
Primary Outcome
Cognitive composite may consist of International Daily Symbol Substitution Test-Medicines (iDSSTm ), International Shopping List Test (ISLT), Continuous Paired Associate Learning Test (CPAL). Time to cognitive worsening is defined as a change in cognitive composite score or any of the individual composite components, from baseline at 2 consecutive visits.
Conditions Studied
Interventions
- OTHER P-tau217 Test
Study Locations (3)
Other
- The University of Tokyo Hospital - Bunkyō City
- Souseikai Sumida Hospital - Tokyo
Texas
- Care Access - Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,400 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2033-07 |
| Phase | Phase 3 |
What NCT07142954 shows while recruiting
NCT07142954 is an interventional study that assigns participants to a tested intervention. Its 3,400 participants enrollment target places it among the larger protocols in the corpus, above the 2,740-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (24% higher).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which P-tau217 Test is the first listed.
NCT07142954 reports a single indexed study location in Other, Texas.
Frequently Asked Questions
What is clinical trial NCT07142954 about?
NCT07142954 is a clinical study titled "Epidemiology and Biomarker Study in Alzheimer's Disease". Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
What is the current status of trial NCT07142954?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,400 participants. The study started on 2025-08-25. Estimated completion is 2033-07.
What conditions does trial NCT07142954 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT07142954?
The interventions under investigation include: P-tau217 Test (OTHER).
Who is sponsoring clinical trial NCT07142954?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07142954 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07142954's enrollment target sits among peer trials
3,400 17th of 306 higher than 290 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
[18F]PI-2620 Phase 3 Histopathological Study
RECRUITING · Phase 3
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RECRUITING · Phase 3
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
RECRUITING · Phase 3
-
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI